Lv51
1264 积分 2024-09-13 加入
Vitiligo
13天前
已完结
Interleukin 15 and autoimmune disorders: pathophysiology, therapeutic potential, and clinical implications
14天前
已完结
The role of interleukin-15 in the spectrum of inflammatory diseases
14天前
已完结
The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2 H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4 H-pyrimido[6,1-a]isoquinolin-4-one]
20天前
已完结
Androgenetic alopecia
1个月前
已完结
Oral SMAD7 Antisense Drug for Crohn's Disease
1个月前
已完结
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
1个月前
已完结
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
1个月前
已完结
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
1个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
1个月前
已完结
皖公网安备34019202002308
